ORIC

SEC source: 0001536368-25-000006 · form4-12092025_101258.xml · nonDerivative · entry 1

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001536368-25-000004 · form4-12052025_101227.xml · derivative · entry 2

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,534 shares

Expires 2032-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022.

SEC source: 0001536368-25-000004 · form4-12052025_101227.xml · nonDerivative · entry 1

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001695028-25-000004 · form4-10082025_091013.xml · derivative · entry 3

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 196,500

Underlying: Common Stock · 11,000 shares

Expires 2032-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001695028-25-000004 · form4-10082025_091013.xml · nonDerivative · entry 2

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,317

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 11,000 shares sold in the price range of $14.50 to $14.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001695028-25-000004 · form4-10082025_091013.xml · nonDerivative · entry 1

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,317

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001608936-25-000010 · form4-10082025_091029.xml · nonDerivative · entry 1

Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 531,419

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 37,461 shares sold in the price range of $12.07 to $12.59 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · balance_after: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.

SEC source: 0001584759-25-000004 · form4-10032025_111055.xml · derivative · entry 6

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,253

Underlying: Common Stock · 1,447 shares

Expires 2032-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable.

SEC source: 0001584759-25-000004 · form4-10032025_111055.xml · derivative · entry 5

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,125 shares

Expires 2028-06-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable.

SEC source: 0001584759-25-000004 · form4-10032025_111055.xml · derivative · entry 4

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,700

Underlying: Common Stock · 13,228 shares

Expires 2028-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable.

SEC source: 0001584759-25-000004 · form4-10032025_111055.xml · nonDerivative · entry 2

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001584759-25-000004 · form4-10032025_111055.xml · nonDerivative · entry 1

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001608936-25-000008 · form4-10022025_111028.xml · nonDerivative · entry 2

Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 568,880

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.

F4 · price: Represents the weighted average share price of an aggregate total of 53,001 shares sold in the price range of $12.00 to $12.13 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · balance_after: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.

SEC source: 0001608936-25-000008 · form4-10022025_111028.xml · nonDerivative · entry 1

Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 621,881

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 34,538 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · balance_after: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.

SEC source: 0001608936-25-000006 · form4-09242025_080916.xml · nonDerivative · entry 1

Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 656,419

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 125,000 shares sold in the price range of $10.57 to $10.92 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · balance_after: Includes 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

F4 · balance_after: The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number.

SEC source: 0001415889-25-019000 · form4-07022025_080708.xml · nonDerivative · entry 1

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,317

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

F2 · price: Represents the weighted average share price of an aggregate total of 20,000 shares sold in the price range of $10.00 to $10.135 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001415889-25-018128 · form4-06242025_100608.xml · nonDerivative · entry 3

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,317

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

F2 · price: Represents the weighted average share price of an aggregate total of 32,466 shares sold in the price range of $10.34 to $10.80 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001415889-25-018014 · form4-06242025_120613.xml · nonDerivative · entry 2

You Angie · CIK 0001647664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

SEC source: 0001415889-25-018128 · form4-06242025_100608.xml · nonDerivative · entry 2

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,783

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

SEC source: 0001415889-25-018128 · form4-06242025_100608.xml · nonDerivative · entry 1

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,233

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

SEC source: 0001415889-25-018014 · form4-06242025_120613.xml · nonDerivative · entry 1

You Angie · CIK 0001647664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,597

F1 · price: Represents the weighted average share price of an aggregate total of 26,597 shares purchased in the price range of $9.14 to $9.50 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001415889-25-017325 · form4-06132025_110620.xml · nonDerivative · entry 1

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,817

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

SEC source: 0001415889-25-016739 · form4-06112025_100647.xml · nonDerivative · entry 3

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,117

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

SEC source: 0001415889-25-016739 · form4-06112025_100647.xml · nonDerivative · entry 2

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,817

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

SEC source: 0001415889-25-016739 · form4-06112025_100647.xml · nonDerivative · entry 1

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,093

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

F2 · balance_after: Includes an aggregate of 1,553 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

SEC source: 0001415889-25-016386 · form4-06102025_120617.xml · nonDerivative · entry 2

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,864

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

SEC source: 0001415889-25-016386 · form4-06102025_120617.xml · nonDerivative · entry 1

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,164

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

F2 · price: Represents the weighted average share price of an aggregate total of 2,600 shares sold in the price range of $10.00 to $10.04 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001415889-25-006616 · form4-03042025_100357.xml · derivative · entry 4

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,500 shares

Expires 2033-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006616 · form4-03042025_100357.xml · derivative · entry 3

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,534

Underlying: Common Stock · 27,666 shares

Expires 2032-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: (A) 20,500 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B) one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022.

SEC source: 0001415889-25-006616 · form4-03042025_100357.xml · nonDerivative · entry 2

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-006616 · form4-03042025_100357.xml · nonDerivative · entry 1

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-000601 · form4-01032025_100150.xml · derivative · entry 2

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,000

Underlying: Common Stock · 34,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

SEC source: 0001415889-25-000601 · form4-01032025_100150.xml · derivative · entry 1

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,500

Underlying: Common Stock · 202,500 shares

Expires 2035-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2026, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

SEC source: 0001415889-25-000600 · form4-01032025_100156.xml · derivative · entry 2

Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

SEC source: 0001415889-25-000600 · form4-01032025_100156.xml · derivative · entry 1

Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 600,000

Underlying: Common Stock · 600,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2026, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

SEC source: 0001415889-25-000602 · form4-01032025_100144.xml · derivative · entry 2

Multani Pratik S · CIK 0001586894 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,000

Underlying: Common Stock · 34,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock.

F3 · derivative.exercise_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

F3 · derivative.expiration_date: 1/3rd of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.

SEC source: 0001415889-25-000602 · form4-01032025_100144.xml · derivative · entry 1

Multani Pratik S · CIK 0001586894 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,500

Underlying: Common Stock · 202,500 shares

Expires 2035-01-01

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2026, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.

SEC source: 0001415889-25-000788 · form4-01062025_090139.xml · derivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025.

SEC source: 0001415889-25-000792 · form4-01062025_090135.xml · derivative · entry 1

Kunkel Lori Anne · CIK 0001536368 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025.

SEC source: 0001415889-25-000782 · form4-01062025_090133.xml · derivative · entry 1

Dier Mardi · CIK 0001574591 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025.

SEC source: 0001415889-25-000785 · form4-01062025_090141.xml · derivative · entry 1

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025.

SEC source: 0001415889-25-000795 · form4-01062025_090153.xml · derivative · entry 1

You Angie · CIK 0001647664 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025.

SEC source: 0001415889-24-029634 · form4-12172024_101232.xml · nonDerivative · entry 2

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,764

F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

F4 · price: Represents the weighted average share price of an aggregate total of 8,851 shares sold in the price range of $8.28 to $8.41 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001415889-24-029631 · form4-12172024_101258.xml · nonDerivative · entry 2

Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 778,648

F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

F4 · price: Represents the weighted average share price of an aggregate total of 24,660 shares sold in the price range of $8.27 to $8.39 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001415889-24-029633 · form4-12172024_101230.xml · nonDerivative · entry 2

Multani Pratik S · CIK 0001586894 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,765

F3 · kind: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

F4 · price: Represents the weighted average share price of an aggregate total of 8,850 shares sold in the price range of $8.27 to $8.41 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001415889-24-029634 · form4-12172024_101232.xml · derivative · entry 5

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

SEC source: 0001415889-24-029634 · form4-12172024_101232.xml · derivative · entry 4

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

F6 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.

F6 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.

SEC source: 0001415889-24-029634 · form4-12172024_101232.xml · derivative · entry 3

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,042 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

F5 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.

F5 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.

SEC source: 0001415889-24-029634 · form4-12172024_101232.xml · nonDerivative · entry 1

Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,615

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

F2 · balance_after: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

SEC source: 0001415889-24-029631 · form4-12172024_101258.xml · derivative · entry 5

Chacko Jacob · CIK 0001608936 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,667

Underlying: Common Stock · 28,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

F7 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

F7 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.